ישראל - עברית - Ministry of Health

taro international ltd, israel - tildrakizumab - תמיסה להזרקה - tildrakizumab 100 mg/ml - tildrakizumab

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - trastuzumab deruxtecan - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab deruxtecan 100 mg - trastuzumab

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - anifrolumab - תרכיז להכנת תמיסה לאינפוזיה - anifrolumab 150 mg/ml - anifrolumab

ישראל - עברית - Ministry of Health

takeda israel ltd - vedolizumab - תמיסה להזרקה - vedolizumab 158.8 mg / 1 ml - vedolizumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - avalglucosidase alpha - אבקה להכנת תמיסה מרוכזת לעירוי - avalglucosidase alpha 100 mg/vial - avalglucosidase alpha

ישראל - עברית - Ministry of Health

sanofi israel ltd - alirocumab - תמיסה להזרקה - alirocumab 150 mg / 1 ml - alirocumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - alirocumab - תמיסה להזרקה - alirocumab 75 mg / 1 ml - alirocumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.